去甲基化药物治疗骨髓增生异常综合征的研究进展

doi:10.3724/SP.J.1005.2013.00136

[an error occurred while processing this directive]

HEREDITAS ›› 2013, Vol. 35 ›› Issue (2): 136-140.doi: 10.3724/SP.J.1005.2013.00136

• en • Previous Articles Next Articles

Application of DNA methyltransferase inhibitors for myelodysplastic syndrome

LÜ Xiao-Yun¹, DU Yun-Xia¹, DAI Zhi-Hong¹, LIU Ming², LIU Xiao-Yu², ZHANG Kai-Li²

1. College of Preclinical Medicine, Dalian Medical University, Dalian 116044, China; 2. Department of Cell Biology, College of Preclinical Medicine, Dalian Medical University, Dalian 116044, China

Received:2012-08-30 Revised:2012-10-22 Online:2013-02-20 Published:2013-02-25

Abstract

Abstract: Epigenetic research plays an important role in the malignant tumor genotyping and tumor clinical treatment recently. Epigenetics is the study of changes in gene function that are mitotically and/or meiotically heritable and that do not entail a change in DNA sequence, including DNA methylation and histone modifications. DNA methylation is one of the most important epigenetic modifications often occurring on the cytosine of CpG islands located in gene promoter regions, which is thought to be closely correlated with tumorigenesis. The inducibility and reversibility of DNA methylation provide us an insight into tumor development and treatment. Aberrant DNA hypermethylation is associated with the progress of myelodysplastic syndrome (MDS). The DNA methyltransferase inhibitors (azacytidine and decitabine) have achieved suc-cess in treating high–and intermediate–risk MDS. This will bring new ideas to understand the cause and develop the treat-ment of MDS. This review mainly introduces the latest progress of the action mechanism of those two medicines, the clini-cal effect and new problems during the clinical application on MDS.

Key words: myelodysplastic syndrome(MDS), DNA demethylation, treatment

Lü Xiao-Yun DU Yun-Xia DAI Zhi-Hong LIU Ming LIU Xiao-Yu ZHANG Kai-Li. Application of DNA methyltransferase inhibitors for myelodysplastic syndrome[J]. HEREDITAS, 2013, 35(2): 136-140.

References

[1] Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res, 2003, 27(2): 95-120.
[2] 陈其文, 田丹杏, 周永明. 骨髓增生异常综合征治疗进展. 医学研究杂志, 2010, 39(8): 119-123.
[3] Matarazzo MR, De Bonis ML, Strazzullo M, Cerase A, Ferraro M, Vastarelli P, Ballestar E, Esteller M, Kudo S, D'Esposito M. Multiple binding of methyl-CpG and poly-comb proteins in long-term gene silencing events. J Cell Physiol, 2007, 210(3): 711-719.
[4] Issa JP. Epigenetic changes in the myelodysplastic syn-drome. Hematol Oncol Clin North Am, 2010, 24(2): 317-330.
[5] Zhou L, Opalinska J, Sohal D, Yu YT, Mo YK, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang JH, Kambhampati S, Parmar S, Nischal S, Hueck C, Suzuki M, Freidman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, McMahon C, Gore SD, Pla-tanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma A. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. J Biol Chem, 2011, 286(28): 25211-25223.
[6] Wu XQ, Liu WL, Tian Y, Xiao M, Wu Y, Li CR. Aberrant Methylation of Death-Associated Protein Kinase 1 CpG Islands in Myelodysplastic Syndromes. Acta Haematol, 2011, 125(4): 179-185.
[7] Fabiani E, Leone G, Giachelia M, D'alo' F, Greco M, Criscuolo M, Guidi F, Rutella S, Hohaus S, Voso MT. Analysis of genome-wide methylation and gene expression induced by 5-aza-2’-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leuk Lymphoma, 2010, 51(12): 2275-2284.
[8] 叶雪石, 刘霆. P15^NK4B基因甲基化与骨髓增生异常综合征. 国外医学: 输血及血液学分册, 2004, 27(1): 63-67.
[9] Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Methylation of p15^INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelo-dysplasia and acute myeloid leukemia. Leukemia, 2003, 17(9): 1813-1819.
[10] Shen LL, Kantarjian H, Guo Y, Lin E, Shan JQ, Huang XL, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JPJ. DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic Syndromes. J Clinical On-col, 2010, 28(4): 605-613.
[11] Bryan J, Kantarjian H, Garcia-Manero G, Jabbour E. Pharmacokinetic evaluation of decitabine for the treatment of leukemia. Expert Opin Drug Metab Toxicol, 2011, 7(5): 661-672.
[12] Hagemann S, Heil O, Lyko F, Brueckner B. Azacytidine and decitabine induce gene-specific and non-random DNA demethylation in human cancer cell lines. PLoS One, 2011, 6(3): e17388.
[13] Giachelia M, D'Alò F, Fabiani E, Saulnier N, Di Ruscio A, Guidi F, Hohaus S, Voso MT, Leone G. Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. Leukemia Res, 2011, 35(4): 465-471.
[14] Desmond JC, Raynaud S, Tung E, Hofmann WK, Hafer-lach T, Koeffler HP. Discovery of epigenetically silenced genes in acute myeloid leukemias. Leukemia, 2007, 21(5): 1026-1034.
[15] Fenaux P, Mufti GJ, Hellström-Lindberg E, Santini V, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LB. Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update. Ecancermedicalscience, 2008, 2: 121.
[16] Götze K, Platzbecker U, Giagounidis A, Haase D, Lübbert M, Aul C, Ganser A, Germing U, Hofmann WK. Azaciti-dine for treatment of patients with myelodysplastic syn-dromes (MDS): practical recommendations of the German MDS Study Group. Ann Hematol, 2010, 89(9): 841-850.
[17] Bordoni RE, Feinbe

Metrics

Comments

www.chinagene.cn
备案号：京ICP备09063187号

Application of DNA methyltransferase inhibitors for myelodysplastic syndrome

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 4

Recommended Articles

Metrics

Comments

[1]	Tian Shu, Haochang Hu, Caijie Shen, Shaoyi Lin, Xiaomin Chen. Research progress of the correlation between genotype and phenotype in hypertrophic cardiomyopathy [J]. Hereditas(Beijing), 2022, 44(3): 198-207.
[2]	Yanni Kou, Shan Cen, Xiaoyu Li. Research and application on LINE-1 in diagnosis and treatment of tumorigenesis [J]. Hereditas(Beijing), 2021, 43(6): 571-579.
[3]	MA Ke, ZHANG A-Mei, XIA Xue-Shan. The function and application of the IL28B gene in HCV infection and treatment [J]. HEREDITAS, 2013, 35(11): 1244-1252.
[4]	XIAO Yao, ZHANG Hua-Lin, BAI Chi-Ya, WANG Xiao-Min, LI Wen-Gong, YANG Li-Guo. Active DNA demethylation in mammals [J]. HEREDITAS, 2011, 33(4): 298-306.